GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Terns Pharmaceuticals
Shares of Terns Pharmaceuticals, a biotech focused on treating gastrointestinal diseases and NASH, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis. We've classified it in the Pharma: Gastrointestinal tract. The chart below shows the dynamics in this competitive yet promising biotech segment.
Broad Market Index - GURU.Markets
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
TERN - Daily change in the company's share price Terns Pharmaceuticals
For Terns, a biopharmaceutical company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with drug development. This metric is a key element in analyzing young biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma git
Terns Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with TERN, a liver-focused company, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Terns is a biopharmaceutical company developing drugs to treat liver diseases. This is a highly competitive and risky field. The chart below shows the segment's volatility, helping to assess how typical Terns' dynamics are for this niche.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Terns Pharmaceuticals
Terns is a biopharmaceutical company specializing in the treatment of gastrointestinal diseases. Its shares are driven by news of clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma git
Terns Pharmaceuticals, Inc. is a clinical-stage biotech developing drugs to treat metabolic diseases such as MASH. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Terns Pharmaceuticals is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Terns Pharmaceuticals
Tyra, a biotech company developing targeted cancer therapies, has sharp monthly fluctuations reflecting the release of clinical trial data. Trial success is key to the company's valuation and determines investor sentiment.
Monthly dynamics of market capitalization of the market segment - Pharma git
Terns Pharmaceuticals is a biotech company focused on treating liver diseases such as nonalcoholic steatohepatitis. This segment of the pharmaceutical industry is attracting significant attention due to the scale of the problem. The industry's dynamics reflect investors' shared hopes for the first effective treatment, and Terns is one of many contenders in this race.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing oral medications for the treatment of non-alcoholic steatohepatitis (NASH) and oncology. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how scientific data has impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Terns Pharmaceuticals
Terns Pharmaceuticals is a biotech company developing drugs to treat liver diseases. Its weekly stock price is volatile and dependent on clinical trial news, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Pharma git
Terns Pharmaceuticals is a biotech company. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its drugs drives share prices independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Terns, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
TERN - Market capitalization of the company Terns Pharmaceuticals
Terns Pharmaceuticals' market capitalization is a story about developing drugs for liver diseases like NASH and oncology. This clinical-stage biotech's stock price reflects investor expectations for its pipeline. Its volatility is a direct market reaction to trial data, which can make or break its value.
TERN - Share of the company's market capitalization Terns Pharmaceuticals within the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and oncology. Its sector share reflects investor expectations for its pipeline. The chart below shows the market's weighting for its chances of success in these challenging areas.
Market capitalization of the market segment - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of nonalcoholic steatohepatitis (NASH) and oncology. The chart below shows the overall market capitalization of the pharmaceutical sector. It illustrates the vast but risky market in which Terns is trying to succeed.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows another company in the race to find a cure for fatty liver disease (NASH). Terns Pharmaceuticals is developing several drugs to treat this disease. Its volatile pipeline is a bet on the success of one of its candidates in this highly competitive but potentially huge therapeutic area.
Book value capitalization of the company, segment and market as a whole
TERN - Book value capitalization of the company Terns Pharmaceuticals
Terns Pharmaceuticals' foundation is its financial reserves and intellectual property in drugs for liver diseases like NASH. This represents focused scientific capital. The chart shows how the biotech company manages its "research budget" as it advances its molecules through the various phases of clinical trials.
TERN - Share of the company's book capitalization Terns Pharmaceuticals within the market segment - Pharma git
Terns Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as NASH. Its assets are intellectual property. The chart shows a minimal share of physical assets, as it is an R&D company in the clinical stage.
Market segment balance sheet capitalization - Pharma git
Developing targeted therapies like Terns' is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Terns Pharmaceuticals' assets are not plants, but capital invested in clinical trials of drugs for the treatment of metabolic diseases, such as NASH, and oncology. The book value reflects the company's financial resources for research in these competitive areas. The chart illustrates its scale in the biotech world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Terns Pharmaceuticals
For Terns, which develops drugs for NASH and cancer, market capitalization reflects its belief in its science. Its ratio to book value (its cash value) reflects how much investors are willing to pay for the potential of its drug candidates in these competitive fields.
Market to book capitalization ratio in a market segment - Pharma git
Terns Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as NASH. Its high valuation on this chart reflects investors' bet that its developments will be successful in this complex and multi-billion-dollar field.
Market to book capitalization ratio for the market as a whole
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment of non-alcoholic steatohepatitis (NASH) and oncology. Its valuation is a bet on the success of its development pipeline. This metric demonstrates the high expectations and volatility that can be faced by companies targeting large markets with unmet medical needs.
Debts of the company, segment and market as a whole
TERN - Company debts Terns Pharmaceuticals
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, is raising capital to fund the development of drugs for metabolic diseases. This chart shows the company's financial needs, which must cover years of R&D expenses before generating any revenue, making it entirely dependent on investors.
Market segment debts - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nonalcoholic steatohepatitis (NASH) and cancer. This chart shows how the company funds its expensive and risky clinical programs by raising capital from investors in hopes of bringing new treatments for serious diseases to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Terns Pharmaceuticals
Terns Pharmaceuticals is a biopharmaceutical company focused on developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Clinical trials in this area are complex and expensive. This chart illustrates the company's reliance on debt to finance its long-term and risky research and development.
Market segment debt to market segment book capitalization - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for liver diseases such as NASH. This chart shows how the company finances its lengthy and expensive clinical trials, relating its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). This represents a huge potential market, but research is expensive and risky. How reliant is the company on debt? This chart of total market debt provides context for assessing its financial strength.
P/E of the company, segment and market as a whole
P/E - Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nonalcoholic steatohepatitis (NASH) and cancer. This chart shows how investors value its pipeline. The valuation is volatile and depends on news about the progress of clinical trials.
P/E of the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart shows the average valuation for the sector, providing investors with context for assessing Terns' scientific potential.
P/E of the market as a whole
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for liver diseases such as NASH and cancer. Valuing such companies is a bet on the success of clinical trials. Does comparing this chart reveal the extent to which investors in Terns are ignoring the broader market picture in favor of its science?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Terns Pharmaceuticals
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). This chart reflects market expectations for the success of its clinical trials. Future profits depend on a breakthrough in the treatment of this common disease.
%20P%2FE%20Terns%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Terns-Pharmaceuticals&v=1772604657921 "Chart of the company's future (projected) P/E Terns Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart shows industry forecasts, allowing for a comparison of how the market views Terns' pipeline of candidates in this highly complex and competitive therapeutic area.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-git&v=1772604657980 "Future (projected) P/E graph of the market segment - Pharma git")
Future (projected) P/E of the market as a whole
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on treating liver diseases such as nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The company's valuation reflects the promise of a breakthrough. This chart shows how willing investors are to invest in solving complex medical problems.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772604658012 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Terns Pharmaceuticals
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as NAFLD. Being in clinical trials, it has no commercial revenue. This chart illustrates the financial side of biotechnology: significant investments in research in the hopes of creating a breakthrough drug.
Profit of companies in the market segment - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and other liver diseases. This chart, which reflects the pharmaceutical sector's profitability, is an important indicator of the investment climate. NASH is a huge market with no approved drugs, and Terns' success depends on the data from its clinical programs.
Overall market profit
Terns Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases such as non-alcoholic steatohepatitis (NASH). This represents a huge market with an unmet need. This overall profitability chart reflects the state of the economy, which influences the willingness of investors and large pharmaceutical companies to invest in long-term and risky clinical development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart represents the quintessence of analyst expectations regarding the success of clinical trials and the potential of their drugs in a market with significant unmet needs.
%20profit%20of%20the%20company%20Terns%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Terns-Pharmaceuticals&v=1772604658213 "Graph of future (projected) profit of the company Terns Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. Its future depends on the success of clinical trials. This biotech chart reflects the general investor confidence that effective solutions will be found for this widespread disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-git&v=1772604658327 "Graph of future (predicted) profits of companies in a market segment - Pharma git")
Future (predicted) profit of the market as a whole
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating liver diseases. Its primary driver is successful research. However, the overall economic climate, illustrated by this chart, influences the availability of capital for biotech companies and their market valuations.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772604658424 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Terns Pharmaceuticals
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat chronic liver diseases, such as NASH, and cancer. For a clinical-stage company, this chart is key. It shows how investors evaluate the potential future sales of its drugs, betting on success in areas of high medical need.
P/S market segment - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as nonalcoholic steatohepatitis (NASH). Its valuation is based on the future potential of its clinical candidates. This chart, which displays the average valuation in the biotech industry, helps understand how investors' expectations for Terns' pipeline compare to overall trends.
P/S of the market as a whole
Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart, which reflects market revenue estimates, serves as a benchmark for Terns' expectations. It demonstrates the value investors place on the company's development pipeline in one of the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biotechnology company focused on developing drugs for the treatment of non-alcoholic steatohepatitis (NASH) and cancer. This schedule reflects investor expectations for successful completion of trials and entry into the vast liver disease treatment market, where no approved drugs currently exist.
%20P%2FS%20Terns%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Terns-Pharmaceuticals&v=1772604658705 "The graph of the company's future (projected) P/S Terns Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases. This chart reflects average future revenue expectations in the pharmaceutical sector. It provides an insight into how the market perceives Terns' potential in this competitive field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20git&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-git&v=1772604658780 "Future (projected) P/S market segment graph - Pharma git")
Future (projected) P/S of the market as a whole
Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for liver diseases such as nonalcoholic steatohepatitis (NASH). This indicator reflects collective market expectations. Terns' success in developing an effective drug for this common condition could unlock a multibillion-dollar market and change the lives of millions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772604658823 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Terns Pharmaceuticals
This chart illustrates the revenue of Terns Pharmaceuticals, a clinical-stage biopharmaceutical company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). At this stage, its revenue, if any, is generated through partnerships, reflecting research progress rather than sales.
Sales of companies in the market segment - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. This chart shows the potential hepatology market. Terns' success in developing effective therapies could lead to breakthrough treatments for millions of patients.
Overall market sales
Terns Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of liver diseases. Its future depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the investment climate in the biotech sector and the availability of funding for R&D.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases, such as NASH, and cancer. Its revenue projections are based on expectations of clinical trial success. The chart reflects analysts' confidence in its scientific developments.
%20sales%20of%20the%20company%20Terns%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Terns-Pharmaceuticals&v=1772604659090 "Schedule of future (projected) sales of the company Terns Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat chronic liver diseases, such as nonalcoholic steatohepatitis (NASH) and viral hepatitis. This chart shows the forecast for the entire pharmaceutical market, where liver disease represents one of the largest unmet medical needs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-git&v=1772604659191 "Schedule of future (projected) sales of companies in the market segment - Pharma git")
Future (projected) sales of the market as a whole
Terns Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases such as nonalcoholic steatohepatitis (NASH). Its future depends on the success of clinical trials. This chart illustrates the overall investment climate, but for Terns, the key is scientific proof of the effectiveness of its drugs in an area with a huge unmet medical need.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772604659257 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Terns Pharmaceuticals
Terns Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as NASH. Being in the clinical stage, it incurs significant R&D expenses. This chart shows its net losses—investments in trying to solve one of the most common and complex problems in modern hepatology and create a blockbuster.
Market segment marginality - Pharma git
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for nonalcoholic steatohepatitis (NASH) and cancer. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the company's potential in very large and complex markets.
Market marginality as a whole
Terns Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of liver diseases, such as non-alcoholic steatohepatitis (NASH), and cancer. This overall profitability chart is irrelevant for them. Their value and prospects are determined entirely by the results of their clinical trials and the market potential of their molecules.
Employees in the company, segment and market as a whole
Number of employees in the company Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biotech focused on treating liver diseases such as NASH. Its small team consists of drug development experts. Growth on this chart will indicate advancement of its candidates into later, larger-scale clinical trials.
Share of the company's employees Terns Pharmaceuticals within the market segment - Pharma git
Terns Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of nonalcoholic steatohepatitis (NASH) and cancer. This chart shows its share of the total number of researchers in these areas. The growth in this percentage reflects progress in clinical trials and the expansion of the scientific team working on new therapeutic solutions.
Number of employees in the market segment - Pharma git
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of chronic liver diseases such as nonalcoholic steatohepatitis (NASH). This chart reflects employment trends in the highly competitive field of gastroenterology. The growing number of scientists here signals progress in clinical research for this complex disease.
Number of employees in the market as a whole
Terns Pharmaceuticals is a biopharmaceutical company focused on developing treatments for liver diseases, such as nonalcoholic steatohepatitis (NASH), and cancer. Its strategy is to build a portfolio of innovative drugs. This chart shows how biotech companies working on treatments for common and complex diseases attract investment and create jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals is a biotech company specializing in liver diseases (NASH) and cancer. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its drug candidates. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Terns%20Pharmaceuticals%20(TERN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Terns-Pharmaceuticals-TERN&v=1772604659504 "Chart of market capitalization per employee (in thousands of dollars) of the company Terns Pharmaceuticals (TERN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma git
Terns Pharmaceuticals is a biotech company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). Its value is based on the potential of its clinical programs. This chart shows the market's high valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-git&v=1772604659553 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma git")
Market capitalization per employee (in thousands of dollars) for the overall market
Terns Pharmaceuticals is a biopharmaceutical company developing drugs to treat liver diseases such as non-alcoholic steatohepatitis (NASH). The chart reflects the estimated scientific potential in a field with a huge market. The company's entire value is based on the hope of successful clinical trials.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772604659574 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals is a clinical-stage biotech company specializing in developing drugs for the treatment of liver diseases, particularly nonalcoholic steatohepatitis (NASH). This research-intensive R&D program is a key focus for research. This chart shows the research intensity: the amount of capital spent on each scientist attempting to solve one of the most complex problems in modern medicine.
%20Chart%20Terns%20Pharmaceuticals%20(TERN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Terns-Pharmaceuticals-TERN&v=1772604659658 "Company Profit Per Employee (in thousands of dollars) Chart Terns Pharmaceuticals (TERN)")
Profit per employee (in thousands of dollars) in the market segment - Pharma git
Terns Pharmaceuticals (TERN) is a clinical-stage biotech focused on the treatment of liver disease (NASH) and cancer. This metric (loss per employee) reflects the high cost of R&D and clinical trials in these complex therapeutic areas.
%20in%20the%20market%20segment%20-%20Pharma%20git&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-git&v=1772604659698 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma git")
Profit per employee (in thousands of dollars) for the market as a whole
Terns Pharmaceuticals is a clinical-stage biotech company specializing in the treatment of NASH (liver disease) and oncology. It is an R&D company and is not profitable. This chart shows the company's capital burn rate: the operating loss per research team developing a new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772604659710 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals is a biopharmaceutical company focused on treating liver diseases such as nonalcoholic steatohepatitis (NASH). This chart reflects the progress of monetizing its research. Revenue at this stage likely comes from partnerships, and the growth in revenue per employee is an indicator of interest in its research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Terns-Pharmaceuticals-TERN&v=1772604659790 "Sales chart per company employee Terns Pharmaceuticals (TERN)")
Sales per employee in the market segment - Pharma git
Terns Pharmaceuticals is a biotech company focused on developing drugs for liver diseases, specifically NASH. This chart shows how productive their research team is. It measures revenue (likely from partnerships) per researcher, comparing them to other companies in the segment.
Sales per employee for the market as a whole
Terns Pharmaceuticals (TERN) is a clinical-stage biotech company specializing in the treatment of liver diseases (such as NAFLD) and oncology. The company does not yet have commercial revenue. This chart illustrates a typical situation in the R&D sector: a team of highly qualified scientists working on the development of future drugs consumes investment capital.
Short shares by company, segment and market as a whole
Shares shorted by company Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals is a biotech company also focused on treating NASH (a liver disease) and cancer. This chart shows bearish bets. Investors shorting TERN, like other companies in this field, are extremely skeptical about the likelihood of success in developing a NASH treatment, given the company's history of failures.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Terns-Pharmaceuticals-TERN&v=1772604660034 "Short Shares Chart for the Company Terns Pharmaceuticals (TERN)")
Shares shorted by market segment - Pharma git
Terns Pharmaceuticals is a biotech company developing drugs to treat NASH (fatty liver disease) and cancer. This chart shows bearish sentiment. The "shorts" here are betting on failure in the biotech "graveyard" (NASH). Investors are betting that their drugs will fail clinical trials.
Shares shorted by the overall market
Terns Pharmaceuticals is a clinical-stage biotech company working on drugs for gastrointestinal diseases and cancer. When this chart shows rising fear, investors indiscriminately sell off all unprofitable companies. For TERN, this means the market doesn't care about their science—only how quickly they run out of money.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals (TERN) is a biotech company focused on treating nonalcoholic steatohepatitis (NASH, or "fatty liver") and other metabolic diseases. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to competitor failures or successes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Terns-Pharmaceuticals-TERN&v=1772604660158 "RSI 14 indicator chart for the company's stock Terns Pharmaceuticals (TERN)")
RSI 14 Market Segment - Pharma git
Terns (TERN) is a biotech company focused on treating MASH (non-alcoholic steatohepatitis) and obesity. The RSI_14_Seg for "Pharma Metabolism" (biotech) shows the overall sentiment. It helps us understand whether TERN's volatility is a reaction to their trials or general hype in the sector.
RSI 14 for the overall market
Terns (TERN) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TERN (Terns Pharmaceuticals)
Terns Pharmaceuticals is a biotech company focused on treating nonalcoholic steatohepatitis (NASH) and other gastrointestinal and liver diseases. This chart shows the average 12-month analyst forecast. It represents their collective speculative bet on clinical trial success in the highly complex but large NASH segment.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TERN-Terns-Pharmaceuticals&v=1772604660305 "A chart showing analyst consensus forecasts for the expected stock price. TERN (Terns Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price TERN (Terns Pharmaceuticals)
Terns Pharma (TERN) is a clinical-stage biotech focused on metabolic diseases, primarily NASH (fatty liver disease) and obesity (GLP-1). This is an R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects how confident analysts are in the company's chances in this highly competitive market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TERN-Terns-Pharmaceuticals&v=1772604660354 "A chart showing the difference between the consensus forecast and the actual stock price. TERN (Terns Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma git
Terns Pharmaceuticals (TERN) is a clinical-stage biotech focused on developing oral therapies (tablets) for the treatment of NASH (fatty liver disease). This chart shows overall expectations for the gastrointestinal pharmaceutical sector. It reflects whether experts believe a breakthrough in the treatment of this "silent epidemic" is imminent.
Analysts' consensus forecast for the overall market share price
Terns Pharmaceuticals (TERN) is an R&D biotech focused on liver diseases (NASH) and gastrointestinal tract diseases. They're burning cash. This chart, reflecting the economic consensus, is their risk appetite. If the consensus is negative (downturn), investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Terns Pharmaceuticals
Terns is a biotech focused on a hot topic: treating NASH (non-alcoholic steatohepatitis, a fatty liver disease) and other metabolic diseases, including obesity. This chart is a pure indicator of biotech expectations. It likely aggregates their clinical trial data (especially for NASH) and market confidence in their chances in this multi-billion-dollar race.
AKIMA Market Segment Index - Pharma git
Terns Pharma (TERN) is a clinical-stage biotech focused on NASH/MASH (liver disease); the company (like Inventiva and 89bio) is developing candidates (oral GLP-1) for this widespread disease. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this highly competitive (NASH) R&D rate (TERN) differentiate it from the average pharma company?
The AKIM Index for the overall market
Terns Pharmaceuticals is a biopharmaceutical company developing small molecules to treat serious diseases, including obesity and MASH. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this competitive landscape in hot therapeutic areas compares to overall economic trends.
